Portal hypertension

Current Opinion in Gastroenterology

Volumn 19, Issue 3, 2003, Pages 250-258

  Garcia Tsao, Guadalupe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADSORBENT; ALBUMIN; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; COTRIMOXAZOLE; FLUMAZENIL; ISOSORBIDE 5 NITRATE; N(G) METHYLARGININE; NADOLOL; NEUROTOXIN; NORFLOXACIN; OCTREOTIDE; PROBIOTIC AGENT; PROPRANOLOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN; SOMATOSTATIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ASCITES; BACTERIAL PERITONITIS; BLEEDING; BLOOD VOLUME; BRAIN DISEASE; CLINICAL TRIAL; DRUG POTENTIATION; HEPATORENAL SYNDROME; HUMAN; HYPOTENSION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER SINUSOID; PARACENTESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; SCLEROTHERAPY; SIDE EFFECT; SODIUM RETENTION; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

EID: 0037404811     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200305000-00008     Document Type: Review

References (59)

1. Van de Casteele M, Omasta A, Janssens S, et al.: In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anesthetised carbon tetrachloride cirrhotic rats. Gut 2002, 51:440-445. Experimental study of effective gene therapy for portal hypertension.
2. Bhathal PS, Grossman HJ: Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985, 1:325-337.
3. Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW, et al.: Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology 2002, 36:381-385.
4. Graupera M, Garcia-Pagan JC, Titos E, et al.: 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology 2002, 122:386-393.
5. Albornoz L, Motta A, Alvarez D, et al.: Nitric oxide synthase activity in the splanchnic vasculature of patients with cirrhosis: relation with hemodynamic disturbances. J Hepatol 2001, 35:456.
6. Wiest R, Groszmann RJ: The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. Hepatology 2002, 35:478-491. Comprehensive review summarizing available data regarding the complex interactions of NO in portal hypertension (too much in the extrahepatic circulation, not enough in the intrahepatic circulation).
7. Tazi KA, Barriere E, Moreau R, et al.: Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology 2002, 122:1869-1877.
8. Spahr L, Martin PY, Giostra E, et al.: Acute effects of nitric oxide synthase inhibition on systemic, hepatic, and renal hemodynamics in patients with cirrhosis and ascites. J Invest Med 2002, 50:116-124.
9. Iwakiri Y, Cadelina G, Sessa WC, et al.: Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol 2002, 263:G1074-G1081.
10. Song D, Liu H, Sharkey K A, et al.: Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology 2002, 35:159-166.
11. Vorobioff J, Gamen M, Kravetz D, et al.: Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial Gastroenterology 2002, 122:916-922. As octreotide blunts the postprandial increase in portal pressure not prevented by long-term propranolol, it could be a useful adjuvant to propranolol in the treatment of portal hypertension.
12. Banares R, Moitinho E, Matilla A, et al.: Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002, 36:1367-1373.
13. De BK, Das D, Sen S, et al.: Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol 2002, 17:183-189.
14. Escorsell A, Gines A, Llach J, et al.: Increasing intra-abdominal pressure increases pressure, volume, and wall tension in esophageal varices. Hepatology 2002, 36:936-940.
15. Jensen DM: Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology 2002, 122:1620-1630.
16. Schepis F, Camma C, Niceforo D, et al.: Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? Hepatology 2001, 33:333-338.
17. Lui HF, Stanley AJ, Forrest EH, et al.: Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol and isosorbide mononitrate. Gastroenterology 2002, 123:735-744.
18. Borroni G, Salerno F, Cazzaniga M, et al.: Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol 2002, 37:315-321.
19. Abraczinkas DR, Ookubo R, Grace N D, et al.: Propranolol for the prevention of first variceal hemorrhage: a lifetime commitment? Hepatology 2001, 34:1096-1102.
20. D'Amico G, Pietrosi G, Tarantino I, et al.: Emergency sclerotherapy versus medical interventions for bleeding esophageal varices in cirrhotic patients. Cochrane Database Syst Rev 2002, 1:CD002233.
21. Banares R, Albillos A, Rincon D, et al.: Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002, 305:609-615. This meta-analysis shows that the ideal therapy for acute variceal hemorrhage is probably a combination of endoscopic and pharmacologic therapy.
22. Moitinho E, Planas R, Banares R, et al.: Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001, 35:712-718.
23. Sarin SK, Jain A K, Jain M, et al.: A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol 2002, 97:1010-1015.
24. Zargar SA, Javid G, Khan B A, et al.: Endoscopic ligation compared with sclerotherapy for bleeding esophageal varices in children with extrahepatic portal venous obstruction. Hepatology 2002, 36:666-672.
25. D'Amico G, Pagliaro L, Bosch J: Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liv Dis 1999, 19:475-505.
26. Villanueva C, Minana J, Ortiz J, et al.: Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001, 345:647-655.
27. Lo G-H, Chen W-C, Chen M-H, et al.: A prospective, randomized trial of endoscopic variceal ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002, 123:728-734.
28. Patch D, Goulis J, Gerunda G, et al.: A randomised controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002, 123:1013-1019.
29. Groszmann RJ, Garcia-Tsao G: Endoscopic variceal banding vs pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference? Gastroenterology 2002, 123:1388-1391.
30. DeFranchis R, Primignani M: Endoscopic treatment for portal hypertension. Semin Liv Dis 1999, 19:439-455.
31. Singh P, Pooran N, Indaram A, et al.: Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a meta-analysis. Am J Gastroenterol 2002, 97:623-629.
32. Escorsell A, Banares R, Garcia-Pagan JC, et al.: TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002, 35:385-392.
33. Gulberg V, Schepke M, Geigenberger G, et al.: Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scand J Gastroenterol 2002, 37:338-343.
34. La Villa G, Barletta G, Pantaleo P, et al.: Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001, 34:19-27.
35. Lebrec D, Giuily N, Hadengue A, et al.: Transjugular intrahepatic podosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996, 25:135-144.
36. Rossle M, Ochs A, Gulberg V, et al.: A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000, 342:1701-1707.
37. Gines P, Uriz J, Calahorra B, et al.: Transjugular intrahepatic portosystemic shunting versus repeated paracentesis plus intravenous albumin for refractory ascites in cirrhosis: a multicenter randomized comparative study. Gastroenterology 2002, 123:1839-1847. Largest study published so far showing no differences in mortality between TIPS and large-volume paracentesis, with greater rates of severe encephalopathy and higher costs with TIPS.
38. Gines A, Fernandez-Esparrach G, Monescillo A, et al.: Randomized trial comparing albumin, dextran-70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996, 111:1002-1010.
39. Ruiz del Arbol L, Monescillo A, Jimenez W, et al.: Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997, 113:579-586.
40. Christidis C, Mal F, Ramos J, et al.: Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001, 35:726-732.
41. Moreau R, Asselah T, Condat B, et al.: Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomized pilot study. Gut 2002, 50:90-94. Interesting preliminary study showing that terlipressin may be as effective as albumin in preventing PCD.
42. Guyader D, Patat A, Ellis-Grosse EJ, et al.: Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002, 36:1197-1205.
43. Arroyo V, Guevara M, Gines P: Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002, 122:1658-1676. Comprehensive review of pathophysiology and current treatment of HRS.
44. Moreau R, Durand F, Poynard T, et al.: Terlipressin in patients with cirrhosis and type I hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002, 122:923-930.
45. Ortega R, Gines P, Uriz J, et al.: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, non-randomized study. Hepatology 2002, 36:941-948.
46. Duvoux C, Zanditenas D, Hezode C, et al.: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002, 36:374-380. This study shows that noradrenaline is an alternative to terlipressin (not available in the United States) in the management of HRS.
47. Fernandez J, Navasa M, Gomez J, et al.: Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002, 35:140-148. Prospective study showing a 320% rate of bacterial infections in cirrhosis and the emergence of infections secondary to quinolone-resistant organisms in patients on long-term prophylaxis.
48. Bauer TM, Follo A, Navasa M, et al.: Daily norfloxacin is mere effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Dig Dis Sci 2002, 47:1356-1361.
49. Bauer TM, Fernandez J, Navasa M, et al.: Failure of Lactobacillus spp. to prevent bacterial tranelocation in a rat model of experimental cirrhosis. J Hepatol 2002, 36:501-506.
50. Such J, Frances R, Munoz C, et al.: Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002, 36:135-141.
51. Wiest R, Das S, Cadelina G, et al.: Bacterial translocation to lymph nodes of cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999, 104:1223-1233.
52. Rabiller A, Nunes H, Lebrec D, et al.: Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 2002, 166:514-517. Experimental study showing that long-term norfloxacin administration abolishes GNB translocation and ameliorates systemic and pulmonary vasodilatation.
53. Ferenci P, Lockwood A, Mullen KD, et al.: Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congresses of Gastroenterology. Vienna, 1998. Hepatology 2002, 35:721. Much-needed consensus document on nomenclature for the clinical diagnosis and guidelines for the performance of future clinical trials on hepatic encephalopathy.
54. Romero-Gomez M, Grande L, Camacho I, et al.: Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. J Hepatol 2002, 37:781-787.
55. Weissenborn K, Ennen JC, Schomerus H, et al.: Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001, 34:768-773.
56. Kircheis G, Wettstein M, Timmerman L, et al.: Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002, 35:357-366.
57. Weissenborn K: Minimal hepatic encephalopathy: a permanent source of discussion. Hepatology 2002, 35:494-496.
58. Goulenok C, Bernard B, Cadranel J F, et al.: Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2002, 16:361-372.
59. Heemann U, Treichel U, Loock J, et al.: Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002, 36:949-958. Interesting randomized study showing that MARS is associated with an improvement in 30-day survival and in hepatic encephalopathy.